Navigation Links
TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process

RESEARCH TRIANGLE PARK, N.C., April 23, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today a strategic relationship with Microsoft Corp. that will help it extend the reach of its drug discovery process. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries will apply to identify inhibitors of 25 biological targets.

TeraDiscoveries will use its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.

"Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. Our approach searches this space much more efficiently and cost-effectively than traditional methods," says Ed Addison, CEO of TeraDiscoveries. "Our strategic relationship with Microsoft enables us to partner with smaller pharmaceutical or medical research companies in the pursuit of these molecules."

"Windows Azure is an open and flexible cloud platform that has the scale and reliability to enable the type of computing power needed by software like Inverse Design," says Doug Hauger, General Manager, Windows Azure Business Development, Microsoft. "We're pleased to be able to support the work done by TeraDiscoveries to help advance its drug discovery process."

Companies can license Inverse Design and run it on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in booth MP-10 at the Bio-IT World Conference & Expo taking place April 24 to 26, 2012, in Boston.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically improve upon traditional drug discovery and design methods. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit or contact Ed Addison at or (910) 398-1200.  

All product and company names herein may be trademarks of their respective owners.

SOURCE TeraDiscoveries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverseons Founder and SAB Member Published in PNAS
2. Inverseon Announces Positive Phase IIa Asthma Study
3. TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
4. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
5. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
6. Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012
7. Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP
8. Sensors in Design Summit Launches at Design West
9. Medical Design & Manufacturing Conference to be Launched in Texas in March 2012
10. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):